NEW YORK (GenomeWeb News) — Ventana Medical Systems’ board of directors has advised stockholders to reject Roche’s unsolicited, $3 billion bid to buy the company on the grounds that the $75-a-share offer is “inadequate in multiple respects and contrary to the best interests of Ventana’s stockholders,” the board stated this morning.
 
Ventana’s closing price on June 25 was $51.74 a share, the day Roche made its offer.
  

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.